A new white paper from BioDlink, From Complexity to Consistency: How CDMOs Can Unlock One-Step, High-Yield and Homogeneous ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Creative Biolabs provides a one-stop solution from R&D to in vitro evaluation, speeding up ADC projects and satisfying the need for ADC products worldwide. SHIRLEY ...

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...

Samsung Biologics to offer ADC services at new dedicated facility Extended collaboration reflects successful partnership and expertise "The latest collaboration will further strengthen Samsung ...

License from Synaffix focuses on bispecific ADCs This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation ...

Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract ...

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 million ...

Xiaojuan Shi currently serves as the Director of Cellular Products Research and Development at ACROBiosystems. With 20+ expertise in pharmaceutical industry platform and product technology research ...

Elevation Oncology (ELEV) announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to ...